These Marijuana Stocks Are The Type Of Companies Investors WantWhen it comes to finding marijuana stocks to buy a happy medium or silver lining at this time is tough to do. Not becuase the low share prices from some of the top-performing companies dont look appetizing. It is more due to the consistent falls in the sector no real upward push. Even as the cannabis industry as a whole is thriving and showing great long-term success.The public sector is not seeing anything transfer over that would show investor ...

EDMONTON, AB, March 31, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has been named an honouree on the Globe & Mail's 2025 Report on Business, Women Lead Here list. This annual editorial benchmark recognizes the top publicly traded Canadian companies with the highest gender diversity at the executive level. Canada's Largest Medical Cannabis Company is an Honouree in The Globe and Mail's 2025 Report on Business Magazine's sixth ...

Core Insights - Aurora Cannabis Inc. is participating as a leader in the inaugural Global Cannabis Regulatory Summit (GCRS) in Washington, D.C. on March 26-27, 2025, highlighting its role in advocating for policy reform in the cannabis industry [1][2] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [3] - The company offers a diverse portfolio of adult-use brands including Drift, San Rafael '71, Daily Special, Tasty's, Being, and Greybeard, as well as medical cannabis brands such as MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co. [3] - Aurora also holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [3] Industry Engagement - The GCRS will facilitate discussions among regulators, members of Congress, international policy experts, and cannabis industry executives to shape the future of the global cannabis industry [2][3] - Aurora's participation in panel discussions aims to enhance understanding of the distinctions between medical and adult-use cannabis, informed by international political and regulatory consensus [3]

Core Insights - Aurora Cannabis Inc. has discovered a novel source of genetic resistance against powdery mildew (PM2), which will enhance the protection of cannabis sativa against this pathogen [1][3] - The proprietary genetic marker technology developed will be integrated into Aurora's breeding program, aiming for commercial launch of powdery mildew resistant cultivars within the year [1][2] Industry Impact - This discovery addresses a significant challenge in the global cannabis industry, providing a sustainable solution for disease management and enhancing agricultural productivity [2][3] - The advancement in genetic research positions Aurora as a leader in the cannabis sector, differentiating it from competitors by focusing on scientific excellence and innovation [2][4] Research Collaboration - The research was led by Principal Scientist Jose Celedon in collaboration with The University of British Columbia, emphasizing the importance of breeding genetic resistance for sustainable agriculture [3][11] - The findings are documented in a peer-reviewed article, highlighting the scientific rigor behind the discovery [5][11] Business Strategy - Aurora's commitment to scientific research and innovation has resulted in improved potency and yield, ultimately reducing production costs and increasing efficiency [4] - The company aims to enhance biosecurity, reduce costs, and improve product quality through this genetic advancement, creating new market opportunities [3][9]

Industry Overview - Marijuana stocks are experiencing a downward trend due to regulatory uncertainty and oversupply in certain regions, leading to falling prices and negatively impacting revenue [1][2] - Despite the challenges, the cannabis industry as a whole continues to grow, with many companies reporting stronger profits and gains in recent earnings reports [2] Investment Opportunities - Current market conditions may present a buying opportunity for investors, as the sector is at a low point [2] - Shareholders are advised to conduct thorough research and monitor the sector closely, as the cannabis industry is still developing and may see positive changes [3] Company Highlights - **Aurora Cannabis Inc.**: Engages in the production, distribution, and sale of cannabis products, recently announced an expansion of pastille offerings in Australia [4][6] - **SNDL Inc.**: Operates in the cannabis sector with various segments, recently reported Q4 2024 and full-year earnings [7][9] - **Cronos Group Inc.**: Focuses on cultivation and marketing of cannabis products, recently appointed Anna Shlimak as CFO [12][13] Financial Performance - **Cronos Group Inc.**: Reported net revenue of $257.7 million for Q4 2024 and $920.4 million for the full year, with gross profit reaching $68.8 million in Q4 and $240.3 million for the year [14]

Group 1 - Aurora Cannabis Inc. is currently ranked 2 (Buy) in the Zacks Rank system, indicating a strong potential for outperforming the market in the next one to three months [3] - The Zacks Consensus Estimate for Aurora Cannabis Inc.'s full-year earnings has increased by 2400% over the past 90 days, reflecting a significant improvement in analyst sentiment [3] - Year-to-date, Aurora Cannabis Inc. has returned approximately 3.8%, outperforming the average return of 3.4% for the Medical sector [4] Group 2 - Aurora Cannabis Inc. belongs to the Medical - Products industry, which consists of 83 individual stocks and is currently ranked 141 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Products industry this year is 6.1%, indicating that Aurora Cannabis Inc. is slightly underperforming its industry [5] - Concentra Group, another Medical stock, has outperformed the sector with a year-to-date return of 5.1% and also holds a Zacks Rank of 2 (Buy) [4][5]

Industry Overview - The cannabis industry is expanding beyond traditional flower sales to include edibles, oils, and wellness products, attracting a broader consumer base [1] - Partnerships among companies to create and release new products are positively impacting the industry [1] Market Dynamics - Companies demonstrating productivity and profitability can influence the trading of marijuana stocks, amidst speculation and volatility [2] - Legal operators are showing progress, leading to improved financial results driven by higher sales, operational efficiencies, and better supply chain management [2] - Evolving regulations are becoming more transparent and standardized, reducing uncertainty for investors and companies [2] Investment Insights - Monitoring trends within the public cannabis sector can provide insights into which marijuana stocks may perform better [3] - A strategic approach is essential for investors to capitalize on market movements, as pot stocks often exhibit unpredictable trading patterns [3] Company Highlights - **Cronos Group Inc.**: Engages in the cultivation, production, and marketing of cannabis products in Canada, Israel, and Germany [4][6] - **Aurora Cannabis Inc.**: Reported Q4 2024 net revenue of $30.3 million, an increase of $6.4 million from Q4 2023, with gross profit rising to $10.8 million [9] - **Canopy Growth Corporation**: Announced a new at-the-market equity program allowing the issuance and sale of up to US$200 million of common shares [13]

Company Performance - Aurora Cannabis Inc. has gained approximately 25.9% year-to-date, significantly outperforming the Medical sector, which has returned an average of 6.8% during the same period [4] - The Zacks Consensus Estimate for Aurora Cannabis Inc.'s full-year earnings has increased by 2400% over the past quarter, indicating a strong improvement in analyst sentiment and earnings outlook [3] Industry Context - Aurora Cannabis Inc. is part of the Medical - Products industry, which consists of 83 individual stocks and currently ranks 79 in the Zacks Industry Rank. The average gain for this group is 10.7% year-to-date, showing that Aurora is performing better than its industry peers [6] - Another stock in the Medical sector that has outperformed is AdaptHealth Corp., which has increased by 11.8% year-to-date [4]

Core Viewpoint - Aurora Cannabis Inc. (ACB) shares have increased by 50.8% in the past four weeks, closing at $5.61, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $7.05, representing a 25.7% upside [1] Price Targets - The average of five short-term price targets ranges from a low of $5.74 to a high of $8.73, with a standard deviation of $1.30, indicating variability among analysts [2] - The lowest estimate suggests a 2.3% increase from the current price, while the highest estimate indicates a 55.6% upside [2] Analyst Consensus and Earnings Estimates - Analysts show strong agreement in revising ACB's earnings estimates higher, which is a positive indicator for potential stock upside [4][9] - The Zacks Consensus Estimate for the current year has increased by 560% due to one estimate moving higher without any negative revisions [10] Zacks Rank - ACB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside [11] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][5] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [6] - A low standard deviation among price targets indicates a high degree of agreement among analysts, which can be a starting point for further research [7]

Group 1: Aurora Cannabis Inc. (ACB) - Aurora Cannabis has a Zacks Rank 1 and its current year earnings estimate increased by 560% over the last 60 days [1] - The company's shares gained 35.0% over the last three months, outperforming the S&P 500's increase of 2.5% [1] - Aurora Cannabis possesses a Momentum Score of A [1] Group 2: Burke & Herbert Financial Services Corp. (BHRB) - Burke & Herbert Financial Services has a Zacks Rank 1 and its current year earnings estimate increased by 6.6% over the last 60 days [2] - The company's shares gained 4.8% over the last month, compared to the S&P 500's increase of 0.7% [2] - Burke & Herbert Financial Services possesses a Momentum Score of B [2] Group 3: BJ's Wholesale Club Holdings, Inc. (BJ) - BJ's Wholesale Club has a Zacks Rank 1 and its current year earnings estimate increased by 0.3% over the last 60 days [3] - The company's shares gained 7.1% over the last three months, outperforming the S&P 500's increase of 2.5% [3] - BJ's Wholesale Club possesses a Momentum Score of B [3]